Patent · US Active

Compositions and methods for inhibiting expression of transthyretin

US9234196B2 · kind B2 · utility

13Cited by

6References

37Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Dinah Wen-Yee Sah · Boston, US
Gregory Hinkle · Plymouth, US
Rene Alvarez · Boxborough, US
Stuart Milstein · Cambridge, US
Qingmin Chen · Wuxi, CN

Key dates

Filing date	Mar 20, 2014
Grant date	Jan 12, 2016
Priority date	—
Expiry date	Mar 20, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.